Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Oct 4;8(1):14797.
doi: 10.1038/s41598-018-33196-2.

A Clinical Risk Prediction Tool for Peritonitis-Associated Treatment Failure in Peritoneal Dialysis Patients

Collaborators, Affiliations
Multicenter Study

A Clinical Risk Prediction Tool for Peritonitis-Associated Treatment Failure in Peritoneal Dialysis Patients

Surapon Nochaiwong et al. Sci Rep. .

Abstract

A tool to predict peritonitis-associated treatment failure among peritoneal dialysis (PD) patients has not yet been established. We conducted a multicentre, retrospective cohort study among 1,025 PD patients between 2006 and 2016 in Thailand to develop and internally validate such a tool. Treatment failure was defined as either a requirement for catheter removal, a switch to haemodialysis, or peritonitis-associated mortality. Prediction model performances were analysed using discrimination (C-statistics) and calibration (Hosmer-Lemeshow test) tests. Predictors were weighted to calculate a risk score. In total, 435 patients with 855 episodes of peritonitis were identified; 215 (25.2%) episodes resulted in treatment failure. A total risk score of 11.5 was developed including, diabetes, systolic blood pressure <90 mmHg, and dialysate leukocyte count >1,000/mm3 and >100/mm3 on days 3-4 and day 5, respectively. The discrimination (C-statistic = 0.92; 95%CI, 0.89-0.94) and calibration (P > 0.05) indicated an excellent performance. No significant difference was observed in the internal validation cohort. The rate of treatment failure in the different groups was 3.0% (low-risk, <1.5 points), 54.4% (moderate-risk, 1.5-9 points), and 89.5% (high-risk, >9 points). A simplified risk-scoring scheme to predict treatment failure may be useful for clinical decision making regarding PD patients with peritonitis. External validation studies are needed.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The AuROC Curve and 95% CI of the Prediction Score of Treatment Failure in PD-Related Peritonitis. Abbreviations: AuROC, area under the receiver operating characteristic; CI, confidence interval; PD, peritoneal dialysis.
Figure 2
Figure 2
Treatment Failure in PD-Related Peritonitis According to the Simplified Risk Category (804 Episodes). Abbreviations: PD, peritoneal dialysis.
Figure 3
Figure 3
Proposed Risk-Stratification Algorithm for Clinical-Decision Making on the Appropriate Strategy of Care for PD-related Peritonitis, According to Their Level of Risk of Treatment Failure. Abbreviations: DM, diabetes mellitus; HD, haemodialysis; IP, intraperitoneal; IV, intravenous; PD, peritoneal dialysis; SBP, systolic blood pressure.

References

    1. Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The Current State of Peritoneal Dialysis. J Am Soc Nephrol. 2016;27:3238–3252. doi: 10.1681/ASN.2016010112. - DOI - PMC - PubMed
    1. Li PK, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13:90–103. doi: 10.1038/nrneph.2016.181. - DOI - PubMed
    1. Li PK, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit Dial Int. 2016;36:481–508. doi: 10.3747/pdi.2016.00078. - DOI - PMC - PubMed
    1. Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis. 2014;64:278–289. doi: 10.1053/j.ajkd.2014.02.025. - DOI - PubMed
    1. Howard K, et al. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial. Am J Kidney Dis. 2015;65:773–779. doi: 10.1053/j.ajkd.2014.12.017. - DOI - PubMed

Publication types